Charles River Laboratories International, Inc.

NYSE:CRL

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

United States

Market Cap

USD 7.24 B

Share Price

USD 147.45

Avg Daily Volume

1,622,587

Change (1 day)

1.49%

Change (1 year)

-29.66%

Change (YTD)

-20.12%

Charles River Laboratories International, Inc. Enterprise Value to EBITDA (EV/EBITDA) on June 20, 2025: 18.15

Charles River Laboratories International, Inc. Enterprise Value to EBITDA (EV/EBITDA) is 18.15 on June 20, 2025, a 34.94% change year over year. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.

Charles River Laboratories International, Inc. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 20.38 on June 20, 2025, which is 12.27% above the current Enterprise Value to EBITDA (EV/EBITDA).
Charles River Laboratories International, Inc. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 11.11 on June 20, 2025, which is -38.78% below the current Enterprise Value to EBITDA (EV/EBITDA).
Charles River Laboratories International, Inc. average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is 14.75.

Daily

From:

To:

Zoom:

Key data

Date	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield	Dividend Yield	Market Capitalization

NYSE: CRL

Charles River Laboratories International, Inc.

CEO	Mr. James C. Foster J.D.
IPO Date	June 23, 2000
Location	United States
Headquarters	251 Ballardvale Street
Employees	18,700
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.